PolyPid partners with Azurity to commercialize D-PLEX100 in US, Canada
PYPD•Exclusive commercialization deal for D-PLEX100
PolyPid entered an exclusive deal with Azurity to commercialize D-PLEX100 in the US and Canada for surgical site infection prevention.
- Upfront payment set at USD 15 million on signing.
- USD 15 million milestone due on FDA NDA acceptance, expected in August 2026.
- Eligible for about USD 300 million in additional regulatory, development and sales milestones, plus tiered royalties in the mid-teens to mid-twenties.
- PolyPid will manufacture and supply D-PLEX100.
- Azurity will fund clinical development, including potential US and Canada label expansion beyond abdominal surgery.
- US launch targeted for Q1 2027.
